Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis
Immunotherapy is revolutionizing the treatment of kidney cancer [1]. In recent years, immune checkpoint inhibitors (ICIs) have been developed and immune-combination therapies have dramatically changed the landscape of first-line treatment in metastatic renal cell carcinoma (mRCC) [2]. Indeed, the armamentarium of systemic therapy available in the first-line is governed by combination therapies, including programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1) inhibitors [1].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Keiichiro Mori, Benjamin Pradere, Fahad Quhal, Satoshi Katayama, Hadi Mostafaei, Ekaterina Laukhtina, Victor M. Schuettfort, David D'Andrea, Shin Egawa, Karim Bensalah, Manuela Schmidinger, Thomas Powles, Shahrokh F. Shariat Tags: Systematic or Meta-analysis Studies Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Immunotherapy | Kidney Cancer | Renal Cell Carcinoma | Study | Toxicology | Urology & Nephrology